Literature DB >> 1954574

Serotypes and subtypes of Neisseria meningitidis serogroup B strains associated with meningococcal disease in Canada, 1977-1989.

F E Ashton1, L Mancino, A J Ryan, J T Poolman, H Abdillahi, W D Zollinger.   

Abstract

Typing of Neisseria meningitidis serogroup B disease isolates was carried out using a panel of serotype-and subtype-specific monoclonal antibodies (MAbs) in enzyme-linked immunosorbent assays (ELISA). Three hundred and sixty-two strains isolated from 1977 to 1986 were typed using five serotyping and seven subtyping reagents and outer membrane vesicles as antigens. Serotype 2b accounted for 30% of the disease isolates. The most common subtype was P1.2, which occurred on 18.5% of all strains or 48.6% of the serotype 2b strains. Of the 362 strains typed, 135 (37.3%) were serotyped and 122 (33.7%) were subtyped. Overall, 185 (51.1%) of the strains could be assigned a serotype and (or) subtype. Strains (221) isolated during the years 1987-1989 were typed using a panel of 6 serotyping and 12 subtyping reagents by whole-cell ELISA. Strains of serotypes 4 (21.7%) and 15 (20.8%) were the most common and carried a wide variety of subtypes. The most common subtypes were P1.2 (11.8%) and P1.16 (9.5%). Of the 221 strains analyzed, 132 (59.7%) were assigned a serotype and 123 (55.7%) a subtype and with all 18 MAbs, 192 (86.9%) of the strains were serotyped and (or) subtyped. Two different MAbs to the four epitopes 2a, 15, P1.2, and P1.16 gave discordant reactions of 0.3, 6.6, 2.6, and 2.2%, respectively, when used to analyze over 300 strains of N. meningitidis.

Entities:  

Mesh:

Year:  1991        PMID: 1954574     DOI: 10.1139/m91-104

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  15 in total

1.  Redesignation of a purported P1.15 subtype-specific meningococcal monoclonal antibody as a P1.19-specific reagent.

Authors:  E Wedege; D A Caugant; A Musacchio; N B Saunders; W D Zollinger
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

2.  Usefulness of the DNA-fingerprinting pattern and the multilocus enzyme electrophoresis profile in the assessment of outbreaks of meningococcal disease.

Authors:  N Weis; I Lind
Journal:  Epidemiol Infect       Date:  1996-04       Impact factor: 2.451

3.  Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model.

Authors:  Duzhang Zhu; Ying Zhang; Vicki Barniak; Liesel Bernfield; Alan Howell; Gary Zlotnick
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Serotypes and subtypes of Neisseria meningitidis: results of an international study comparing sensitivities and specificities of monoclonal antibodies.

Authors:  J T Poolman; P Kriz-Kuzemenska; F Ashton; W Bibb; J Dankert; A Demina; L O Frøholm; M Hassan-King; D M Jones; I Lind
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

5.  Invasive meningococcal disease in Scotland, 1994 to 1999, with emphasis on group B meningococcal disease.

Authors:  Moe H Kyaw; Stuart C Clarke; Peter Christie; Ian G Jones; Harry Campbell
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

6.  Potential capsule switching from serogroup Y to B: The characterization of three such Neisseria meningitidis isolates causing invasive meningococcal disease in Canada.

Authors:  Raymond Sw Tsang; Dennis Ks Law; Shaun D Tyler; Gwen S Stephens; Mark Bigham; Wendell D Zollinger
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-05       Impact factor: 2.471

7.  Genomic fingerprinting of Neisseria meningitidis associated with group C meningococcal disease in Canada.

Authors:  C A Strathdee; S D Tyler; J A Ryan; W M Johnson; F E Ashton
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

8.  Meningococcal infections in the Province of Québec, Canada, during the period 1991 to 1992.

Authors:  L Ringuette; M Lorange; A Ryan; F Ashton
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

9.  Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada.

Authors:  F E Ashton; J A Ryan; A Borczyk; D A Caugant; L Mancino; D Huang
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

Review 10.  Current status of meningococcal group B vaccine candidates: capsular or noncapsular?

Authors:  J Diaz Romero; I M Outschoorn
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.